^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Neuroblastoma

    Related cancers:
    1d
    GLOW-FISH: An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma (clinicaltrials.gov)
    P1/2, N=22, Recruiting, Princess Maxima Center for Pediatric Oncology
    New P1/2 trial • First-in-human
    2d
    18F-DOPA II - PET Imaging Optimization (clinicaltrials.gov)
    P3, N=800, Recruiting, University of Alberta | Trial completion date: Jul 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    2d
    IMMUNEORGANOID: Engineering Immune Organoids to Study Pediatric Cancer (clinicaltrials.gov)
    P=N/A, N=108, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | N=44 --> 108
    Enrollment change
    2d
    ONITT: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    2d
    SJFAMILY: Familial Investigations of Childhood Cancer Predisposition (clinicaltrials.gov)
    P=N/A, N=1500, Recruiting, St. Jude Children's Research Hospital | N=3000 --> 1500
    Enrollment change
    2d
    Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons. (PubMed, Front Oncol)
    All sensitivity unadjusted and adjusted comparisons supported the results of the base-case analysis. Dinutuximab beta significantly prolonged OS compared to historical control cohorts not treated with dB in both unadjusted and adjusted indirect comparisons.
    Journal
    |
    IL2 (Interleukin 2)
    |
    Qarziba (dinutuximab beta)
    2d
    Arginine-axis transcriptomics define three neuroblastoma subtypes and a fixed four-gene prognostic signature with immune correlations. (PubMed, Transl Pediatr)
    Aggregated CMap analysis nominated histone deacetylase (HDAC) inhibition, with entinostat (MS-275) ranking highest as a candidate to reverse the high-risk transcriptomic program. An Arg-axis-anchored approach resolves biologically coherent NB subtypes and yields a parsimonious, fixed-coefficient four-gene signature that generalizes across cohorts, aligns with immune contexture, and proposes testable therapeutic hypotheses. These results support metabolism-informed risk stratification in NB and motivate prospective validation with standardized processing, mechanistic flux assays, and rational combination studies.
    Journal • IO biomarker
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    Jingzhuda (entinostat)
    5d
    PI3Kγ Pathway Contributes to Neuroinflammation and Neuronal Death Induced by Zika Virus Infection. (PubMed, Immunology)
    These findings suggest that PI3Kγ activation facilitates ZIKV infection and exacerbates neuroinflammation. Pharmacological inhibition of the PI3Kγ pathway may offer therapeutic benefits by limiting viral replication and alleviating neuroinflammatory responses during ZIKV infection.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • IL17A (Interleukin 17A)
    5d
    NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Baylor College of Medicine | Trial completion date: Dec 2043 --> Apr 2044 | Initiation date: Nov 2025 --> May 2026 | Trial primary completion date: Dec 2028 --> Apr 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    NKG2D (killer cell lectin like receptor K1)
    6d
    Involvement of Keap1/Nrf2 and the antioxidant defence in cytoprotective effects induced by cannabis polyphenols in SH-SY5Y neuronal cells. (PubMed, Biomed Pharmacother)
    In silico docking studies identified Leu583 as a key residue in Nrf2-ligand interactions. These findings suggest that Cannabis sativa L. polyphenols are key bioactive compounds modulating redox homeostasis and inflammation, and offering neuroprotective benefits with potential relevance in diseases involving mitochondrial dysfunction and oxidative damage.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • KEAP1 (Kelch Like ECH Associated Protein 1) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • PRDX1 (Peroxiredoxin 1) • BAX (BCL2-associated X protein) • PRDX3 (Peroxiredoxin 3)